These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1054 related items for PubMed ID: 27758138

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma.
    Lan X, Zhang H, Wang Z, Dong W, Sun W, Shao L, Zhang T, Zhang D.
    Gene; 2015 Sep 10; 569(1):109-17. PubMed ID: 26003293
    [Abstract] [Full Text] [Related]

  • 3. Identification of Long Noncoding RNAs Deregulated in Papillary Thyroid Cancer and Correlated with BRAFV600E Mutation by Bioinformatics Integrative Analysis.
    Goedert L, Plaça JR, Fuziwara CS, Machado MCR, Plaça DR, Almeida PP, Sanches TP, Santos JFD, Corveloni AC, Pereira IEG, de Castro MM, Kimura ET, Silva WA, Espreafico EM.
    Sci Rep; 2017 May 10; 7(1):1662. PubMed ID: 28490781
    [Abstract] [Full Text] [Related]

  • 4. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
    Song B, Li R, Zuo Z, Tan J, Liu L, Ding D, Lu Y, Hou D.
    BMC Cancer; 2019 Apr 02; 19(1):297. PubMed ID: 30940124
    [Abstract] [Full Text] [Related]

  • 5. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, Accardo G, Sacco V, Bellastella A, Pannone G.
    Thyroid; 2011 Apr 02; 21(4):391-9. PubMed ID: 21385081
    [Abstract] [Full Text] [Related]

  • 6. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
    Liao T, Qu N, Shi RL, Guo K, Ma B, Cao YM, Xiang J, Lu ZW, Zhu YX, Li DS, Ji QH.
    Oncotarget; 2017 Jan 03; 8(1):238-247. PubMed ID: 27462868
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.
    Eur J Endocrinol; 2013 May 03; 168(5):675-81. PubMed ID: 23416953
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H, Li W, Yan P, Bundschuh R, Killian JA, Labanowska J, Brock P, Shen R, Heerema NA, de la Chapelle A.
    Thyroid; 2018 Jun 03; 28(6):748-754. PubMed ID: 29768105
    [Abstract] [Full Text] [Related]

  • 12. Expression profile of long noncoding RNAs in human papillary thyroid carcinoma.
    Cao Y, Shi C, Li J, Liang Y, Qiu J, Yuan L, Yong Z, Zhang DX, Shi GQ.
    Neoplasma; 2019 Mar 05; 66(2):245-251. PubMed ID: 30569720
    [Abstract] [Full Text] [Related]

  • 13. BRAF-Activated Long Noncoding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor.
    Zheng H, Wang M, Jiang L, Chu H, Hu J, Ning J, Li B, Wang D, Xu J.
    Cancer Res Treat; 2016 Apr 05; 48(2):698-707. PubMed ID: 26323637
    [Abstract] [Full Text] [Related]

  • 14. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM, Gu J, Zhang YS, Wei WJ, Qu N, Wen D, Liao T, Shi RL, Zhang L, Ji QH, Wang Y, Sun GH, Zhao YX, Wang YJ, Yu J, Zhu YX.
    Oncol Rep; 2018 Jan 05; 39(1):338-348. PubMed ID: 29115628
    [Abstract] [Full Text] [Related]

  • 15. Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer.
    Ma B, Liao T, Wen D, Dong C, Zhou L, Yang S, Wang Y, Ji Q.
    Sci Rep; 2016 Nov 11; 6():36973. PubMed ID: 27833134
    [Abstract] [Full Text] [Related]

  • 16. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 17. Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
    Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z, Teng W, Xing M.
    Cancer; 2008 Jul 15; 113(2):247-55. PubMed ID: 18470905
    [Abstract] [Full Text] [Related]

  • 18. Oncogenic Properties of the Antisense lncRNA COMET in BRAF- and RET-Driven Papillary Thyroid Carcinomas.
    Esposito R, Esposito D, Pallante P, Fusco A, Ciccodicola A, Costa V.
    Cancer Res; 2019 May 01; 79(9):2124-2135. PubMed ID: 30862713
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive analysis of long noncoding RNA-mRNA co-expression patterns in thyroid cancer.
    Du Y, Xia W, Zhang J, Wan D, Yang Z, Li X.
    Mol Biosyst; 2017 Sep 26; 13(10):2107-2115. PubMed ID: 28817151
    [Abstract] [Full Text] [Related]

  • 20. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
    Xing M.
    Endocr Rev; 2007 Dec 26; 28(7):742-62. PubMed ID: 17940185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.